ARPI Combinations Extend Progression-Free Survival in Metastatic Hormone-Sensitive Prostate Cancer
Men with metastatic hormone-sensitive prostate cancer experienced longer progression-free survival when treated with ARPI doublets rather than docetaxel plus ADT.
In metastatic hormone-sensitive prostate cancer, treatment decisions involve choosing among systemic approaches, and the headline focuses on progression-free survival as a key comparison. The summary indicates that ARPI doublets were associated with longer progression-free survival than docetaxel plus ADT in this patient group. It does not provide details on trial design, patient numbers, or the size of the difference, so the result should be read within that limited context.
For men with metastatic hormone-sensitive prostate cancer and their clinicians, a longer progression-free survival signal for ARPI doublets could shape treatment discussions and follow-up planning. Caregivers may also face changed expectations and logistical demands if such regimens are used more widely. Health systems could see shifts in treatment pathways, though the summary does not establish cost, access, or overall survival effects.